This study is looking at how well a drug called Indocyanine Green (ICG) can help surgeons find and remove solid tumors or lymphoma in children. ICG is an FDA-approved drug that is given through a vein before surgery. During the operation, a special imaging system (EleVision™ IR Platform) will be used to see if the ICG helps highlight the tumor and its edges. This could help surgeons make sure they remove all of the tumor, which is very important for a cure. The main goal is to see how accurately ICG can identify the tumor during surgery. You might be able to join if you have a primary or relapsed solid tumor or lymphoma that needs to be removed. You cannot join if you have iodide allergies, benign (non-cancerous) pathology, or brain tumors. The study is currently unclear about its recruitment status and plans to enroll 230 participants.

Study design

This is a single-center, open-label study, meaning both you and the study team will know you are receiving Indocyanine Green. It plans to include 230 participants.

What's involved

You will receive a single dose of Indocyanine Green intravenously the day before surgery. Your tumor will be imaged during surgery, and the study participation will last until 24 hours after surgery.

Compensation

Not stated in the trial record.

Follow-up

Your direct participation in the trial will last until 24 hours post-surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.